WHA78 individual statement on non-communicable diseases
On 23 May 2025, IFPMA delivered a statement at the 78th session of the World Health Assembly on non-communicable diseases.
IFPMA welcomes WHO’s continued efforts to tackle one of the greatest health challenges of our lifetimes. We need to capture the political momentum before and during the UN High-Level Meeting in September to bend the curve against NCDs in every country around the world.
In our call to action, we urge Member States to embrace innovation, mobilize investment, drive implementation, and ensure accountability. Our industry remains a committed stakeholder in tackling NCDs. With over 9,600 NCD medicines in the R&D pipeline, we should be optimistic about the benefits that scientific innovation will bring to millions of patients. We will continue working with others to build solutions and contribute towards stronger health systems to improve the lives of people living with NCDs. A life-course approach to preventing and tackling NCDs is the only way to reduce the huge burden placed on patients and healthcare systems worldwide.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
